Citi has initiated coverage of West Pharmaceutical Services (NYSE:WST), a provider of pharmaceutical packaging and injectable ...

West Pharmaceutical Services, Inc. (NYSE:WST – Get Free Report) has received a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports.

Fintel reports that on January 8, 2025, Citigroup initiated coverage of West Pharmaceutical Services (NYSE:WST) with a Buy ...

This was the stock's second consecutive day of losses.

West Pharmaceutical Services (WST) stock is down 16% due to deteriorating fundamentals, with emphasis on future growth ...

West Pharmaceutical Services (WST) has received a new Buy rating, initiated by Citi analyst, Patrick B Donnelly.Stay Ahead of the ...

Shares of West Pharmaceutical Services Inc. WST rose 1.32% to $336.91 Wednesday, on what proved to be an all-around positive ...

Citi initiated coverage of West Pharmaceutical (WST) with a Buy rating and $400 price target West is a provider of packaging and injectable ...

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, ...

West Pharmaceutical Services has a 12-month low of $265.00 and a 12-month high of $413.70. The stock has a market cap of $23.90 billion, a PE ratio of 48.97, a PEG ratio of 25.04 and a beta of 1.01.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.